BACKGROUND: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. OBJECTIVE: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. METHODS: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. RESULTS: Internal consistency was high for all measures (α = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. CONCLUSIONS: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.
BACKGROUND:Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. OBJECTIVE: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. METHODS: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. RESULTS: Internal consistency was high for all measures (α = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. CONCLUSIONS: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.
Authors: Ralph H B Benedict; Elizabeth Wahlig; Rohit Bakshi; Inna Fishman; Frederick Munschauer; Robert Zivadinov; Bianca Weinstock-Guttman Journal: J Neurol Sci Date: 2005-01-26 Impact factor: 3.181
Authors: R A Rudick; G Cutter; M Baier; E Fisher; D Dougherty; B Weinstock-Guttman; M K Mass; D Miller; N A Simonian Journal: Neurology Date: 2001-05-22 Impact factor: 9.910
Authors: D F Cella; K Dineen; B Arnason; A Reder; K A Webster; G karabatsos; C Chang; S Lloyd; J Steward; D Stefoski Journal: Neurology Date: 1996-07 Impact factor: 9.910
Authors: Noelle E Carlozzi; Elizabeth A Hahn; Siera M Goodnight; Anna L Kratz; Jane S Paulsen; Julie C Stout; Samuel Frank; Jennifer A Miner; David Cella; Richard C Gershon; Stephen G Schilling; Rebecca E Ready Journal: Psychol Assess Date: 2017-05-29
Authors: Anna L Kratz; Tiffany J Braley; Emily Foxen-Craft; Eric Scott; John F Murphy; Susan L Murphy Journal: Arch Phys Med Rehabil Date: 2017-07-18 Impact factor: 3.966
Authors: Yujie Wang; Fan Tian; Kathryn C Fitzgerald; Jagriti Jackie Bhattarai; Robert T Naismith; Megan Hyland; Peter A Calabresi; Ellen M Mowry Journal: Mult Scler Relat Disord Date: 2020-02-14 Impact factor: 4.339
Authors: Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald Journal: Mult Scler Relat Disord Date: 2020-11-23 Impact factor: 4.339
Authors: Ellen M Mowry; Robert A Bermel; James R Williams; Tammie L S Benzinger; Carl de Moor; Elizabeth Fisher; Carrie M Hersh; Megan H Hyland; Izlem Izbudak; Stephen E Jones; Bernd C Kieseier; Hagen H Kitzler; Lauren Krupp; Yvonne W Lui; Xavier Montalban; Robert T Naismith; Jacqueline A Nicholas; Fabio Pellegrini; Alex Rovira; Maximilian Schulze; Björn Tackenberg; Mar Tintore; Madalina E Tivarus; Tjalf Ziemssen; Richard A Rudick Journal: Front Neurol Date: 2020-08-07 Impact factor: 4.003
Authors: Isaiah Kletenik; Enrique Alvarez; Justin M Honce; Brooke Valdez; Timothy L Vollmer; Luis D Medina Journal: Mult Scler J Exp Transl Clin Date: 2019-02-13